Document Type

Article

Original Publication Date

2017

Journal/Book/Conference Title

JOURNAL OF CLINICAL HYPERTENSION

Volume

19

Issue

7

First Page

695

Last Page

701

DOI of Original Publication

10.1111/jch.12993

Comments

Originally published at http://doi.org/10.1111/jch.12993

Date of Submission

August 2017

Abstract

The efficacy and safety of azilsartan medoxomil (AZL-M) were evaluated in African-American patients with hypertension in a 6-week, double-blind, randomized, placebo-controlled trial, for which the primary end point was change from baseline in 24-hour mean systolic blood pressure (BP). There were 413 patients, with a mean age of 52years, 57% women, and baseline 24-hour BP of 146/91mmHg. Treatment differences in 24-hour systolic BP between AZL-M 40mg and placebo (-5.0mmHg; 95% confidence interval, -8.0 to -2.0) and AZL-M 80mg and placebo (-7.8mmHg; 95% confidence interval, -10.7 to -4.9) were significant (P.001 vs placebo for both comparisons). Changes in the clinic BPs were similar to the ambulatory BP results. Incidence rates of adverse events were comparable among the treatment groups, including those of a serious nature. In African-American patients with hypertension, AZL-M significantly reduced ambulatory and clinic BPs in a dose-dependent manner and was well tolerated.

Rights

© The Authors and Takeda Development Centers, Americas, Inc and Takeda Pharmaceuticals International. The Journal of Clinical Hypertension published by Wiley Periodicals, Inc.

Is Part Of

VCU Pathology Publications

Share

COinS
 
 
 
View graphic versionView graphic versionView graphic version